Getting comical because it is comical. I predict MRNA breaks .40 cents tomorrow on it way to .25. Volume and chart is telling me so!!
We'll see. I think a lot of us thought that. Scary though that the offering had yet to be approved been after a few months. Thx
Hi Farmer, i guess the few posters on this board are cautiously optimistic, we think we have some good science however we are in a bad position with a company that has one employee remaining and no money. Having said i noticed that the most recent filing on june 17 they reported presentation at conference on june 16, then june 17 they backed off the proposed share sale and said that company is concentrating on "Short term" financing deals through partnerships. I'm wondering if on june 16 after the presentation Mr French had a meeting with someone who promised a pre lim deal that led french to withdraw stock offering on the next day !!!! especially Pro NAI therapeutics now trading after the IPO, they can easily aquire MRNA with a cash and stock deal they can take us for 2 - 3 dollars, i've always thought that we were a better buy out than going it alone. I think we may see some speculative buying in the next few days and if a deal is in the works then we should hear about it any time now. if i had some extra money i would probably buy a few thousand more shares, its now or never for Mr French and MRNA. Again MRNA is a great example of "only invest what you can afford to lose"
Good luck to all
Farmerjimmy, I just don't know. I think this is going to go down to the wire, to see if mrna can cut a deal. What we do know is that the Phase 2 testing and Phase 1 testing interim results (announced approximately 8 months ago) were positive and there is every indication they will be when the studies are completed. We also know about partnership "possibilities." I think the question is whether the studies are competed and partnerships inked before the well runs dry. Anything I would guess is mere conjecture. It looks like some viable products are going to move forward if a deal is signed. The problem is that the leverage of mrna is limited by it's cash position, but if another company wants to make money, they can only do this if it has a deal to move ahead with mrna. The leverage of the parties usually dictates the terms of the contract. But we are in murky water where the very near future is not clear. Hope this works out, but for now I'm in a holding pattern.
You must be from Colorado because nobody except a BIG TIME hooch-smoker would make such and outlandish comment. This company has a $1Mn/Q cash burn and a working capital deficit of over $500k.
Our DNAi platform technology is based on the breakthrough discovery at Wayne State University and Karmanos Cancer Institute that single-stranded DNA oligonucleotides can interact with genomic DNA in order to interfere with gene transcription. We acquired this technology and subsequently developed an algorithm that we employ for rationally designing our DNAi product candidates using bioinformatics and our understanding of gene regulatory domains. In March 2007, we entered into an exclusive license agreement with Novosom AG (Novosom) to use certain patented lipid nanoparticle (LNP) delivery technology used in PNT2258. In July 2010, the original Novosom license agreement was acquired by Marina Biotech, Inc. (Marina), but Novosom retained the right to receive all future payments related to PNT2258. In March 2012, we and Marina entered into another exclusive license agreement for the use of certain of Marina’s patented delivery technology, including LNP technology, for any of our current or future DNAi product candidates other than PNT2258. In exchange for this exclusive right, we paid Marina an upfront payment of $0.3 million and will also be required to pay Marina milestone payments of up to an aggregate of $14.5 million for each DNAi product candidate other than PNT2258 as well as low single-digit royalties on net sales for DNAi product candidates other than PNT2258. In April 2014, we entered into a license payment agreement with Novosom, pursuant to which we made a one-time payment to Novosom of $11.0 million in April 2014 and terminated the other payment obligations owed to Novosom for PNT2258 except for one remaining $3.0 million payment due upon regulatory approval of PNT2258 and a low single-digit royalty on net sales of PNT2258.
ProNAi Therapeutics, which is developing cancer therapies based on DNA interference, raised the proposed deal size for its upcoming IPO on Wednesday.
The Vancouver, Canada-based company now plans to raise $138 million by offering 8.1 million shares at a price of $17. The company had previously filed to offer 6.7 million shares at a range of $14 to $16. At the revised price, ProNAi Therapeutics will raise 37% greater proceeds than previously anticipated.
ProNAi Therapeutics, which was founded in 2003, plans to list on the NASDAQ under the symbol DNAI. Jefferies and BofA Merrill Lynch are the joint bookrunners on the deal. It is expected to price this week.
Licensing of lipid nanoparticles. Pronai is partly based off Marina technology.
gak62, Just watch! Been watching and waiting....what month were they going to walk this up?
Fool and his money. Here we go. It's now or never for French and Marina. I'd hate to see something finally happen and not be in it after all I've put in to this thing over the years. This scuttling of the S-1 might be a head fake, but probably not. It may just be another temporary life-line but at this point our multiple technologies have got to get SOMEBODY'S attention!!... Hopefully somebody who wants to try it ALL out. ....Just for kicks..... At least we'll know what's up - or down - pretty soon.